Learn how frameworks like Solid, Svelte, and Angular are using the Signals pattern to deliver reactive state without the ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the ...
Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...
Hosted on MSN
Cantor Fitzgerald Upgrades Replimune Group (REPL)
Fintel reports that on July 30, 2025, Cantor Fitzgerald upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Overweight. Analyst Price Forecast Suggests 206.26% Upside As of July ...
Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...
Hosted on MSN
Wedbush Downgrades Replimune Group (REPL)
Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results